Wnt and Incretin Connections

Vitamins and Hormones

Volumn 84, Issue C, 2010, Pages 355-387

  García Jiménez, Custodia ^a  

^a UNIVERSIDAD REY JUAN CARLOS   (Spain)

Author keywords

Diabetes; GIP; GLP 1; Glucose dependent insulinotropic peptide; Incretin; Insulin; Metabolism; Obesity; Transcription; Wnt

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; WNT PROTEIN;

ANIMAL; BOOK; MOUSE; PANCREAS ISLET BETA CELL; PHYSIOLOGY; SECRETION;

ANIMALS; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; INSULIN-SECRETING CELLS; MICE; WNT PROTEINS;

EID: 78649372583     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-381517-0.00014-X     Document Type: Book

References (169)

1. Althage M.C., Ford E.L., Wang S., Tso P., Polonsky K.S., Wice B.M. Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet. J. Biol. Chem. 2008, 283:18365-18376.
2. Aslanidi G., Kroutov V., Philipsberg G., Lamb K., Campbell-Thompson M., Walter G.A., Kurenov S., Ignacio Aguirre J., Keller P., Hankenson K., Macdougald O.A., Zolotukhin S. Ectopic expression of Wnt10b decreases adiposity and improves glucose homeostasis in obese rats. Am. J. Physiol. Endocrinol. Metab. 2007, 293:E726-E736.
3. Asmar M., Holst J.J. Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: New advances. Curr. Opin. Endocrinol. Diabetes Obes. 2010, 17:57-62.
4. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
5. Belsham D.D., Fick L.J., Dalvi P.S., Centeno M.L., Chalmers J.A., Lee P.K., Wang Y., Drucker D.J., Koletar M.M. Ciliary neurotrophic factor recruitment of glucagon-like peptide-1 mediates neurogenesis, allowing immortalization of adult murine hypothalamic neurons. FASEB J. 2009, 23:4256-4265.
6. Benhamouche S., Decaens T., Perret C., Colnot S. Wnt/beta-catenin pathway and liver metabolic zonation: A new player for an old concept. Med. Sci. (Paris) 2006, 22:904-906.
7. Berndt T., Craig T.A., Bowe A.E., Vassiliadis J., Reczek D., Finnegan R., Jan De Beur S.M., Schiavi S.C., Kumar R. Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J. Clin. Invest. 2003, 112:785-794.
8. Bikkavilli R.K., Feigin M.E., Malbon C.C. p38 mitogen-activated protein kinase regulates canonical Wnt-beta-catenin signaling by inactivation of GSK3beta. J. Cell Sci. 2008, 121:3598-3607.
9. Blitzer J.T., Nusse R. A critical role for endocytosis in Wnt signaling. BMC Cell Biol. 2006, 7:28.
10. Bollag R.J., Zhong Q., Phillips P., Min L., Zhong L., Cameron R., Mulloy A.L., Rasmussen H., Qin F., Ding K.H., Isales C.M. Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology 2000, 141:1228-1235.
11. Boylan M.O., Jepeal L.I., Jarboe L.A., Wolfe M.M. Cell-specific expression of the glucose-dependent insulinotropic polypeptide gene in a mouse neuroendocrine tumor cell line. J. Biol. Chem. 1997, 272:17438-17443.
12. Brack A.S., Conboy M.J., Roy S., Lee M., Kuo C.J., Keller C., Rando T.A. Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis. Science 2007, 317:807-810.
13. Brown J.C., Otte S. Clinical studies with gastric inhibitory polypeptide. World J. Surg. 1979, 3:553-558.
14. Brubaker P.L. Regulation of intestinal proglucagon-derived peptide secretion by intestinal regulatory peptides. Endocrinology 1991, 128:3175-3182.
15. Brubaker P.L., Schloos J., Drucker D.J. Regulation of glucagon-like peptide-1 synthesis and secretion in the GLUTag enteroendocrine cell line. Endocrinology 1998, 139:4108-4114.
16. Caverzasio J., Manen D. Essential role of Wnt3a-mediated activation of mitogen-activated protein kinase p38 for the stimulation of alkaline phosphatase activity and matrix mineralization in C3H10T1/2 mesenchymal cells. Endocrinology 2007, 148:5323-5330.
17. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127:469-480.
18. Chafey P., Finzi L., Boisgard R., Cauzac M., Clary G., Broussard C., Pegorier J.P., Guillonneau F., Mayeux P., Camoin L., Tavitian B., Colnot S., et al. Proteomic analysis of beta-catenin activation in mouse liver by DIGE analysis identifies glucose metabolism as a new target of the Wnt pathway. Proteomics 2009, 9:3889-3900.
19. Chan C.B., Pederson R.A., Buchan A.M., Tubesing K.B., Brown J.C. Gastric inhibitory polypeptide (GIP) and insulin release in the obese Zucker rat. Diabetes 1984, 33:536-542.
20. Chang J., Sonoyama W., Wang Z., Jin Q., Zhang C., Krebsbach P.H., Giannobile W., Shi S., Wang C.Y. Noncanonical Wnt-4 signaling enhances bone regeneration of mesenchymal stem cells in craniofacial defects through activation of p38 MAPK. J. Biol. Chem. 2007, 282:30938-30948.
21. Christodoulides C., Laudes M., Cawthorn W.P., Schinner S., Soos M., O'Rahilly S., Sethi J.K., Vidal-Puig A. The Wnt antagonist Dickkopf-1 and its receptors are coordinately regulated during early human adipogenesis. J. Cell Sci. 2006, 119:2613-2620.
22. Christophe J. Is there appetite after GLP-1 and PACAP?. Ann. NY Acad. Sci. 1998, 865:323-335.
23. D'Alessio D., Vahl T., Prigeon R. Effects of glucagon-like peptide 1 on the hepatic glucose metabolism. Horm. Metab. Res. 2004, 36:837-841.
24. Davies P.S., Dismuke A.D., Powell A.E., Carroll K.H., Wong M.H. Wnt-reporter expression pattern in the mouse intestine during homeostasis. BMC Gastroenterol. 2008, 8:57.
25. De Ferrari G.V., Moon R.T. The ups and downs of Wnt signaling in prevalent neurological disorders. Oncogene 2006, 25:7545-7553.
26. de Heer J., Rasmussen C., Coy D.H., Holst J.J. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 2008, 51:2263-2270.
27. Ding K.H., Zhong Q., Xu J., Isales C.M. Glucose-dependent insulinotropic peptide: Differential effects on hepatic artery vs. portal vein endothelial cells. Am. J. Physiol. Endocrinol. Metab. 2004, 286:E773-E779.
28. Driskell R.R., Goodheart M., Neff T., Liu X., Luo M., Moothart C., Sigmund C.D., Hosokawa R., Chai Y., Engelhardt J.F. Wnt3a regulates Lef-1 expression during airway submucosal gland morphogenesis. Dev. Biol. 2007, 305:90-102.
29. Drucker D.J. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat. Clin. Pract. Endocrinol. Metab. 2005, 1:22-31.
30. Drucker D.J., Jin T., Asa S.L., Young T.A., Brubaker P.L. Activation of proglucagon gene transcription by protein kinase-A in a novel mouse enteroendocrine cell line. Mol. Endocrinol. 1994, 8:1646-1655.
31. Dumoulin V., Dakka T., Plaisancie P., Chayvialle J.A., Cuber J.C. Regulation of glucagon-like peptide-1-(7-36) amide, peptide YY, and neurotensin secretion by neurotransmitters and gut hormones in the isolated vascularly perfused rat ileum. Endocrinology 1995, 136:5182-5188.
32. Elrick H., Stimmler L., Hlad C.J., Arai Y. Plasma insulin response to oral and intravenous glucose administration. J. Clin. Endocrinol. Metab. 1964, 24:1076-1082.
33. Essers M.A., de Vries-Smits L.M., Barker N., Polderman P.E., Burgering B.M., Korswagen H.C. Functional interaction between beta-catenin and FOXO in oxidative stress signaling. Science 2005, 308:1181-1184.
34. Firestein R., Blander G., Michan S., Oberdoerffer P., Ogino S., Campbell J., Bhimavarapu A., Luikenhuis S., de Cabo R., Fuchs C., Hahn W.C., Guarente L.P., Sinclair D.A. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS ONE 2008, 3:e2020.
35. Flamez D., Gilon P., Moens K., Van Breusegem A., Delmeire D., Scrocchi L.A., Henquin J.C., Drucker D.J., Schuit F. Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes 1999, 48:1979-1986.
36. Florez J.C., Jablonski K.A., Bayley N., Pollin T.I., de Bakker P.I., Shuldiner A.R., Knowler W.C., Nathan D.M., Altshuler D. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N. Engl. J. Med. 2006, 355:241-250.
37. Fujino T., Asaba H., Kang M.J., Ikeda Y., Sone H., Takada S., Kim D.H., Ioka R.X., Ono M., Tomoyori H., Okubo M., Murase T., et al. Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion. Proc. Natl. Acad. Sci. USA 2003, 100:229-234.
38. Gao C., Yao S.K. Diabetes mellitus: A "true" independent risk factor for hepatocellular carcinoma?. Hepatobiliary Pancreat Dis. Int. 2009, 8:465-473.
39. Gao Y., Wang H.Y. Inositol pentakisphosphate mediates Wnt/beta-catenin signaling. J. Biol. Chem. 2007, 282:26490-26502.
40. Garcia-Martinez J.M., Chocarro-Calvo A., Moya C.M., Garcia-Jimenez C. WNT/beta-catenin increases the production of incretins by entero-endocrine cells. Diabetologia 2009, 52:1913-1924.
41. Gebhardt R., Hovhannisyan A. Organ patterning in the adult stage: The role of Wnt/beta-catenin signaling in liver zonation and beyond. Dev. Dyn. 2010, 239:45-55.
42. Gerber M. Background review paper on total fat, fatty acid intake and cancers. Ann. Nutr. Metab. 2009, 55:140-161.
43. Grant S.F., Thorleifsson G., Reynisdottir I., Benediktsson R., Manolescu A., Sainz J., Helgason A., Stefansson H., Emilsson V., Helgadottir A., Styrkarsdottir U., Magnusson K.P., et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat. Genet. 2006, 38:320-323.
44. Gray S.L., Nora E.D., Grosse J., Manieri M., Stoeger T., Medina-Gomez G., Burling K., Wattler S., Russ A., Yeo G.S., Chatterjee V.K., O'Rahilly S., et al. Leptin deficiency unmasks the deleterious effects of impaired peroxisome proliferator-activated receptor gamma function (P465L PPARgamma) in mice. Diabetes 2006, 55:2669-2677.
45. Green B.D., Flatt P.R. Incretin hormone mimetics and analogues in diabetes therapeutics. Best Pract. Res. Clin. Endocrinol. Metab. 2007, 21:497-516.
46. Guo Y.F., Xiong D.H., Shen H., Zhao L.J., Xiao P., Guo Y., Wang W., Yang T.L., Recker R.R., Deng H.W. Polymorphisms of the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with obesity phenotypes in a large family-based association study. J. Med. Genet. 2006, 43:798-803.
47. Gustafson B., Smith U. WNT signalling is both an inducer and effector of glucagon-like peptide-1. Diabetologia 2008, 51:1768-1770.
48. Hansotia T., Baggio L.L., Delmeire D., Hinke S.A., Yamada Y., Tsukiyama K., Seino Y., Holst J.J., Schuit F., Drucker D.J. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 2004, 53:1326-1335.
49. Hansotia T., Maida A., Flock G., Yamada Y., Tsukiyama K., Seino Y., Drucker D.J. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J. Clin. Invest. 2007, 117:143-152.
50. Hartmann H., Ebert R., Creutzfeldt W. Insulin-dependent inhibition of hepatic glycogenolysis by gastric inhibitory polypeptide (GIP) in perfused rat liver. Diabetologia 1986, 29:112-114.
51. Hecht A., Vleminckx K., Stemmler M.P., van Roy F., Kemler R. The p300/CBP acetyltransferases function as transcriptional coactivators of beta-catenin in vertebrates. EMBO J. 2000, 19:1839-1850.
52. Herrmann-Rinke C., Voge A., Hess M., Goke B. Regulation of glucagon-like peptide-1 secretion from rat ileum by neurotransmitters and peptides. J. Endocrinol. 1995, 147:25-31.
53. Hino S., Tanji C., Nakayama K.I., Kikuchi A. Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase stabilizes beta-catenin through inhibition of its ubiquitination. Mol. Cell. Biol. 2005, 25:9063-9072.
54. Hoogeboom D., Essers M.A., Polderman P.E., Voets E., Smits L.M., Burgering B.M. Interaction of FOXO with beta-catenin inhibits beta-catenin/T cell factor activity. J. Biol. Chem. 2008, 283:9224-9230.
55. Hovanes K., Li T.W., Munguia J.E., Truong T., Milovanovic T., Lawrence Marsh J., Holcombe R.F., Waterman M.L. Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nat. Genet. 2001, 28:53-57.
56. Ikezawa Y., Yamatani K., Ohnuma H., Daimon M., Manaka H., Sasaki H. Glucagon-like peptide-1 inhibits glucagon-induced glycogenolysis in perivenous hepatocytes specifically. Regul. Pept. 2003, 111:207-210.
57. Inagaki N., Seino Y., Takeda J., Yano H., Yamada Y., Bell G.I., Eddy R.L., Fukushima Y., Byers M.G., Shows T.B., et al. Gastric inhibitory polypeptide: Structure and chromosomal localization of the human gene. Mol. Endocrinol. 1989, 3:1014-1021.
58. Ingalls A.M., Dickie M.M., Snell G.D. Obese, a new mutation in the house mouse. J. Hered. 1950, 41:317-318.
59. Jin T. Mechanisms underlying proglucagon gene expression. J. Endo 2008, 198:17-28.
60. Jin T., Liu L. The Wnt signaling pathway effector TCF7L2 and type 2 diabetes mellitus. Mol. Endocrinol. 2008, 22:2383-2392.
61. Jones I.R., Owens D.R., Luzio S., Hayes T.M. Glucose dependent insulinotropic polypeptide (GIP) infused intravenously is insulinotropic in the fasting state in type 2 (non-insulin dependent) diabetes mellitus. Horm. Metab. Res. 1989, 21:23-26.
62. Jones I.R., Owens D.R., Luzio S., Williams S., Hayes T.M. The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989, 32:668-677.
63. Kanda Y., Shimoda M., Tawaramoto K., Hamamoto S., Tatsumi F., Kawasaki F., Hashiramoto M., Nakashima K., Matsuki M., Kaku K. Molecular analysis of db gene-related pancreatic beta cell dysfunction; evidence for a compensatory mechanism inhibiting development of diabetes in the db gene heterozygote. Endocr. J. 2009, 56:997-1008.
64. Kawamori D., Kaneto H., Nakatani Y., Matsuoka T.A., Matsuhisa M., Hori M., Yamasaki Y. The forkhead transcription factor Foxo1 bridges the JNK pathway and the transcription factor PDX-1 through its intracellular translocation. J. Biol. Chem. 2006, 281:1091-1098.
65. Kieffer T.J., Habener J.F. The glucagon-like peptides. Endocr. Rev. 1999, 20:876-913.
66. Kieffer T.J., Huang Z., McIntosh C.H., Buchan A.M., Brown J.C., Pederson R.A. Gastric inhibitory polypeptide release from a tumor-derived cell line. Am. J. Physiol. 1995, 269:E316-E322.
67. Kim S.J., Nian C., McIntosh C.H. Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes. A role for a protein kinase B, LKB1, and AMP-activated protein kinase cascade. J. Biol. Chem. 2007, 282:8557-8567.
68. Kinzler K.W., Vogelstein B. Life (and death) in a malignant tumour. Nature 1996, 379:19-20.
69. Knop F.K., Vilsboll T., Hojberg P.V., Larsen S., Madsbad S., Holst J.J., Krarup T. The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance. Regul. Pept. 2007, 144:123-130.
70. Komiya Y., Habas R. Wnt signal transduction pathways. Organogenesis 2008, 4:68-75.
71. Korinek V., Barker N., Morin P.J., van Wichen D., de Weger R., Kinzler K.W., Vogelstein B., Clevers H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997, 275:1784-1787.
72. Kubota T., Michigami T., Ozono K. Wnt signaling in bone metabolism. J. Bone Miner. Metab. 2009, 27:265-271.
73. Kuhnert F., Davis C.R., Wang H.T., Chu P., Lee M., Yuan J., Nusse R., Kuo C.J. Essential requirement for Wnt signaling in proliferation of adult small intestine and colon revealed by adenoviral expression of Dickkopf-1. Proc. Natl. Acad. Sci. USA 2004, 101:266-271.
74. Laurent-Puig P., Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene 2006, 25:3778-3786.
75. Letamendia A., Labbe E., Attisano L. Transcriptional regulation by Smads: Crosstalk between the TGF-beta and Wnt pathways. J. Bone Joint Surg. Am. 2001, 83-A(Suppl. 1):S31-S39.
76. Levy L., Wei Y., Labalette C., Wu Y., Renard C.A., Buendia M.A., Neuveut C. Acetylation of beta-catenin by p300 regulates beta-catenin-Tcf4 interaction. Mol. Cell. Biol. 2004, 24:3404-3414.
77. Li J., Sutter C., Parker D.S., Blauwkamp T., Fang M., Cadigan K.M. CBP/p300 are bimodal regulators of Wnt signaling. EMBO J. 2007, 26:2284-2294.
78. Lillis A.P., Van Duyn L.B., Murphy-Ullrich J.E., Strickland D.K. LDL receptor-related protein 1: Unique tissue-specific functions revealed by selective gene knockout studies. Physiol. Rev. 2008, 88:887-918.
79. Lin F., Wang R. Molecular modeling of the three-dimensional structure of GLP-1R and its interactions with several agonists. J. Mol. Model. 2009, 15:53-65.
80. Liu H., Fergusson M.M., Castilho R.M., Liu J., Cao L., Chen J., Malide D., Rovira I.I., Schimel D., Kuo C.J., Gutkind J.S., Hwang P.M., Finkel T. Augmented Wnt signaling in a mammalian model of accelerated aging. Science 2007, 317:803-806.
81. Liu Z., Habener J.F. Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. J. Biol. Chem. 2008, 283:8723-8735.
82. Loder M.K., da Silva Xavier G., McDonald A., Rutter G.A. TCF7L2 controls insulin gene expression and insulin secretion in mature pancreatic beta-cells. Biochem. Soc. Trans. 2008, 36:357-359.
83. Longo K.A., Kennell J.A., Ochocinska M.J., Ross S.E., Wright W.S., MacDougald O.A. Wnt signaling protects 3T3-L1 preadipocytes from apoptosis through induction of insulin-like growth factors. J. Biol. Chem. 2002, 277:38239-38244.
84. Longo K.A., Wright W.S., Kang S., Gerin I., Chiang S.H., Lucas P.C., Opp M.R., MacDougald O.A. Wnt10b inhibits development of white and brown adipose tissues. J. Biol. Chem. 2004, 279:35503-35509.
85. Lynn F.C., Thompson S.A., Pospisilik J.A., Ehses J.A., Hinke S.A., Pamir N., McIntosh C.H., Pederson R.A. A novel pathway for regulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta cells. FASEB J. 2003, 17:91-93.
86. Lyssenko V. The transcription factor 7-like 2 gene and increased risk of type 2 diabetes: An update. Curr. Opin. Clin. Nutr. Metab. Care 2008, 11:385-392.
87. Lyssenko V., Lupi R., Marchetti P., Del Guerra S., Orho-Melander M., Almgren P., Sjogren M., Ling C., Eriksson K.F., Lethagen A.L., Mancarella R., Berglund G., et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J. Clin. Invest. 2007, 117:2155-2163.
88. MacDougald O.A., Mandrup S. Adipogenesis: Forces that tip the scales. Trends Endocrinol. Metab. 2002, 13:5-11.
89. May P., Woldt E., Matz R.L., Boucher P. The LDL receptor-related protein (LRP) family: An old family of proteins with new physiological functions. Ann. Med. 2007, 39:219-228.
90. McIntosh C.H., Widenmaier S., Kim S.J. Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP). Vitam. Horm. 2009, 80:409-471.
91. McIntyre N., Holdsworth C.D., Turner D.S. Intestinal factors in the control of insulin secretion. J. Clin. Endocrinol. Metab. 1965, 25:1317-1324.
92. Meier J.J., Hucking K., Holst J.J., Deacon C.F., Schmiegel W.H., Nauck M.A. Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes 2001, 50:2497-2504.
93. Merle P., Kim M., Herrmann M., Gupte A., Lefrancois L., Califano S., Trepo C., Tanaka S., Vitvitski L., de la Monte S., Wands J.R. Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma. J. Hepatol. 2005, 43:854-862.
94. Mikels A.J., Nusse R. Wnts as ligands: Processing, secretion and reception. Oncogene 2006, 25:7461-7468.
95. Miller C.P., Lin J.C., Habener J.F. Transcription of the rat glucagon gene by the cyclic AMP response element-binding protein CREB is modulated by adjacent CREB-associated proteins. Mol. Cell. Biol. 1993, 13:7080-7090.
96. Miyawaki K., Yamada Y., Ban N., Ihara Y., Tsukiyama K., Zhou H., Fujimoto S., Oku A., Tsuda K., Toyokuni S., Hiai H., Mizunoya W., et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat. Med. 2002, 8:738-742.
97. Miyawaki K., Yamada Y., Yano H., Niwa H., Ban N., Ihara Y., Kubota A., Fujimoto S., Kajikawa M., Kuroe A., Tsuda K., Hashimoto H., et al. Glucose intolerance caused by a defect in the entero-insular axis: A study in gastric inhibitory polypeptide receptor knockout mice. Proc. Natl. Acad. Sci. USA 1999, 96:14843-14847.
98. Moens K., Heimberg H., Flamez D., Huypens P., Quartier E., Ling Z., Pipeleers D., Gremlich S., Thorens B., Schuit F. Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes 1996, 45:257-261.
99. Moriyama A., Kii I., Sunabori T., Kurihara S., Takayama I., Shimazaki M., Tanabe H., Oginuma M., Fukayama M., Matsuzaki Y., Saga Y., Kudo A. GFP transgenic mice reveal active canonical Wnt signal in neonatal brain and in adult liver and spleen. Genesis 2007, 45:90-100.
100. Murtaugh L.C., Law A.C., Dor Y., Melton D.A. Beta-catenin is essential for pancreatic acinar but not islet development. Development 2005, 132:4663-4674.
101. Naito A.T., Akazawa H., Takano H., Minamino T., Nagai T., Aburatani H., Komuro I. Phosphatidylinositol 3-kinase-Akt pathway plays a critical role in early cardiomyogenesis by regulating canonical Wnt signaling. Circ. Res. 2005, 97:144-151.
102. Nakagawa Y., Kawaguchi Y., Twells R.C., Muxworthy C., Hunter K.M., Wilson A., Merriman M.E., Cox R.D., Merriman T., Cucca F., McKinney P.A., Shield J.P., et al. Fine mapping of the diabetes-susceptibility locus, IDDM4, on chromosome 11q13. Am. J. Hum. Genet. 1998, 63:547-556.
103. Nauck M., Stockmann F., Ebert R., Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986, 29:46-52.
104. Nauck M.A. Unraveling the science of incretin biology. Eur. J. Intern. Med. 2009, 20(Suppl. 2):S303-S308.
105. Nauck M.A., Bartels E., Orskov C., Ebert R., Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J. Clin. Endocrinol. Metab. 1993, 76:912-917.
106. Nauck M.A., Homberger E., Siegel E.G., Allen R.C., Eaton R.P., Ebert R., Creutzfeldt W. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J. Clin. Endocrinol. Metab. 1986, 63:492-498.
107. Ni Z., Anini Y., Fang X., Mills G., Brubaker P.L., Jin T. Transcriptional activation of the proglucagon gene by lithium and beta-catenin in intestinal endocrine L cells. J. Biol. Chem. 2003, 278:1380-1387.
108. Nyberg J., Anderson M.F., Meister B., Alborn A.M., Strom A.K., Brederlau A., Illerskog A.C., Nilsson O., Kieffer T.J., Hietala M.A., Ricksten A., Eriksson P.S. Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation. J. Neurosci. 2005, 25:1816-1825.
109. Orskov C., Rabenhoj L., Wettergren A., Kofod H., Holst J.J. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994, 43:535-539.
110. Parker H.E., Habib A.M., Rogers G.J., Gribble F.M., Reimann F. Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. Diabetologia 2009, 52:289-298.
111. Parker J.C., Irwin N., Lavery K.S., Green B.D., O'Harte F.P., Gault V.A., Flatt P.R. Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9-39)amide in obese diabetic (ob/ob) mice. Biol. Chem. 2007, 388:221-226.
112. Parthier C., Kleinschmidt M., Neumann P., Rudolph R., Manhart S., Schlenzig D., Fanghanel J., Rahfeld J.U., Demuth H.U., Stubbs M.T. Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor. Proc. Natl. Acad. Sci. USA 2007, 104:13942-13947.
113. Pederson R.A., Campos R.V., Buchan A.M., Chisholm C.B., Russell J.C., Brown J.C. Comparison of the enteroinsular axis in two strains of obese rat, the fatty Zucker and the JCR:LA-corpulent. Int. J. Obes. 1991, 15:461-470.
114. Pederson R.A., Satkunarajah M., McIntosh C.H., Scrocchi L.A., Flamez D., Schuit F., Drucker D.J., Wheeler M.B. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice. Diabetes 1998, 47:1046-1052.
115. Perry T., Haughey N.J., Mattson M.P., Egan J.M., Greig N.H. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J. Pharmacol. Exp. Ther. 2002, 302:881-888.
116. Phelps R.A., Broadbent T.J., Stafforini D.M., Jones D.A. New perspectives on APC control of cell fate and proliferation in colorectal cancer. Cell Cycle 2009, 8:2549-2556.
117. Pilgaard K., Jensen C.B., Schou J.H., Lyssenko V., Wegner L., Brons C., Vilsboll T., Hansen T., Madsbad S., Holst J.J., Volund A., Poulsen P., et al. The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men. Diabetologia 2009, 52:1298-1307.
118. Preitner F., Ibberson M., Franklin I., Binnert C., Pende M., Gjinovci A., Hansotia T., Drucker D.J., Wollheim C., Burcelin R., Thorens B. Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J. Clin. Invest. 2004, 113:635-645.
119. Prokunina-Olsson L., Welch C., Hansson O., Adhikari N., Scott L.J., Usher N., Tong M., Sprau A., Swift A., Bonnycastle L.L., Erdos M.R., He Z., et al. Tissue-specific alternative splicing of TCF7L2. Hum. Mol. Genet. 2009, 18:3795-3804.
120. Redondo A., Trigo M.V., Acitores A., Valverde I., Villanueva-Penacarrillo M.L. Cell signalling of the GLP-1 action in rat liver. Mol. Cell. Endocrinol. 2003, 204:43-50.
121. Reimer R.A., Darimont C., Gremlich S., Nicolas-Metral V., Ruegg U.T., Mace K. A human cellular model for studying the regulation of glucagon-like peptide-1 secretion. Endocrinology 2001, 142:4522-4528.
122. Rindi G., Grant S.G., Yiangou Y., Ghatei M.A., Bloom S.R., Bautch V.L., Solcia E., Polak J.M. Development of neuroendocrine tumors in the gastrointestinal tract of transgenic mice. Heterogeneity of hormone expression. Am. J. Pathol. 1990, 136:1349-1363.
123. Ross S.E., Hemati N., Longo K.A., Bennett C.N., Lucas P.C., Erickson R.L., MacDougald O.A. Inhibition of adipogenesis by Wnt signaling. Science 2000, 289:950-953.
124. Rulifson I.C., Karnik S.K., Heiser P.W., ten Berge D., Chen H., Gu X., Taketo M.M., Nusse R., Hebrok M., Kim S.K. Wnt signaling regulates pancreatic beta cell proliferation. Proc. Natl. Acad. Sci. USA 2007, 104:6247-6252.
125. Runge S., Thogersen H., Madsen K., Lau J., Rudolph R. Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain. J. Biol. Chem. 2008, 283:11340-11347.
126. Salinas P.C., Zou Y. Wnt signaling in neural circuit assembly. Annu. Rev. Neurosci. 2008, 31:339-358.
127. Sancho V., Trigo M.V., Gonzalez N., Valverde I., Malaisse W.J., Villanueva-Penacarrillo M.L. Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats. J. Mol. Endocrinol. 2005, 35:27-38.
128. Saxena R., Gianniny L., Burtt N.P., Lyssenko V., Giuducci C., Sjogren M., Florez J.C., Almgren P., Isomaa B., Orho-Melander M., Lindblad U., Daly M.J., et al. Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes 2006, 55:2890-2895.
129. Scrocchi L.A., Brown T.J., MaClusky N., Brubaker P.L., Auerbach A.B., Joyner A.L., Drucker D.J. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat. Med. 1996, 2:1254-1258.
130. Schinner S., Ulgen F., Papewalis C., Schott M., Woelk A., Vidal-Puig A., Scherbaum W.A. Regulation of insulin secretion, glucokinase gene transcription and beta cell proliferation by adipocyte-derived Wnt signalling molecules. Diabetologia 2008, 51:147-154.
131. Schinner S., Willenberg H.S., Krause D., Schott M., Lamounier-Zepter V., Krug A.W., Ehrhart-Bornstein M., Bornstein S.R., Scherbaum W.A. Adipocyte-derived products induce the transcription of the StAR promoter and stimulate aldosterone and cortisol secretion from adrenocortical cells through the Wnt-signaling pathway. Int. J. Obes. (Lond.) 2007, 31:864-870.
132. Schinner S., Willenberg H.S., Schott M., Scherbaum W.A. Pathophysiological aspects of Wnt-signaling in endocrine disease. Eur. J. Endocrinol. 2009, 160:731-737.
133. Sharma M., Chuang W.W., Sun Z. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation. J. Biol. Chem. 2002, 277:30935-30941.
134. Shu L., Matveyenko A.V., Kerr-Conte J., Cho J.H., McIntosh C.H., Maedler K. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. Hum. Mol. Genet. 2009, 18:2388-2399.
135. Shu L., Sauter N.S., Schulthess F.T., Matveyenko A.V., Oberholzer J., Maedler K. Transcription factor 7-like 2 regulates beta-cell survival and function in human pancreatic islets. Diabetes 2008, 57:645-653.
136. Sinclair E.M., Drucker D.J. Proglucagon-derived peptides: Mechanisms of action and therapeutic potential. Physiology (Bethesda) 2005, 20:357-365.
137. Strathmann J., Paal K., Ittrich C., Krause E., Appel K.E., Glauert H.P., Buchmann A., Schwarz M. Proteome analysis of chemically induced mouse liver tumors with different genotype. Proteomics 2007, 7:3318-3331.
138. Suzuki A., Ozono K., Kubota T., Kondou H., Tachikawa K., Michigami T. PTH/cAMP/PKA signaling facilitates canonical Wnt signaling via inactivation of glycogen synthase kinase-3beta in osteoblastic Saos-2 cells. J. Cell. Biochem. 2008, 104:304-317.
139. Tang W., Dodge M., Gundapaneni D., Michnoff C., Roth M., Lum L. A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. Proc. Natl. Acad. Sci. USA 2008, 105:9697-9702.
140. Terrand J., Bruban V., Zhou L., Gong W., El Asmar Z., May P., Zurhove K., Haffner P., Philippe C., Woldt E., Matz R.L., Gracia C., et al. LRP1 controls intracellular cholesterol storage and fatty acid synthesis through modulation of Wnt signaling. J. Biol. Chem. 2009, 284:381-388.
141. Theodorakis M.J., Carlson O., Michopoulos S., Doyle M.E., Juhaszova M., Petraki K., Egan J.M. Human duodenal enteroendocrine cells: Source of both incretin peptides, GLP-1 and GIP. Am. J. Physiol. Endocrinol. Metab. 2006, 290:E550-E559.
142. Thornton T.M., Pedraza-Alva G., Deng B., Wood C.D., Aronshtam A., Clements J.L., Sabio G., Davis R.J., Matthews D.E., Doble B., Rincon M. Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation. Science 2008, 320:667-670.
143. Tian E., Zhan F., Walker R., Rasmussen E., Ma Y., Barlogie B., Shaughnessy J.D. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med. 2003, 349:2483-2494.
144. Toledo E.M., Colombres M., Inestrosa N.C. Wnt signaling in neuroprotection and stem cell differentiation. Prog. Neurobiol. 2008, 86:281-296.
145. Tolhurst G., Reimann F., Gribble F.M. Nutritional regulation of glucagon-like peptide-1 secretion. J. Physiol. 2009, 587:27-32.
146. Tseng C.C., Boylan M.O., Jarboe L.A., Usdin T.B., Wolfe M.M. Chronic desensitization of the glucose-dependent insulinotropic polypeptide receptor in diabetic rats. Am. J. Physiol. 1996, 270:E661-E666.
147. Tseng C.C., Zhang X.Y. Role of G protein-coupled receptor kinases in glucose-dependent insulinotropic polypeptide receptor signaling. Endocrinology 2000, 141:947-952.
148. Twells R.C., Metzker M.L., Brown S.D., Cox R., Garey C., Hammond H., Hey P.J., Levy E., Nakagawa Y., Philips M.S., Todd J.A., Hess J.F. The sequence and gene characterization of a 400-kb candidate region for IDDM4 on chromosome 11q13. Genomics 2001, 72:231-242.
149. Usdin T.B., Mezey E., Button D.C., Brownstein M.J., Bonner T.I. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 1993, 133:2861-2870.
150. van Es J.H., Jay P., Gregorieff A., van Gijn M.E., Jonkheer S., Hatzis P., Thiele A., van den Born M., Begthel H., Brabletz T., Taketo M.M., Clevers H. Wnt signalling induces maturation of Paneth cells in intestinal crypts. Nat. Cell Biol. 2005, 7:381-386.
151. Vella A., Rizza R.A. Extrapancreatic effects of GIP and GLP-1. Horm. Metab. Res. 2004, 36:830-836.
152. Vilsboll T., Krarup T., Deacon C.F., Madsbad S., Holst J.J. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001, 50:609-613.
153. Vilsboll T., Krarup T., Madsbad S., Holst J.J. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul. Pept. 2003, 114:115-121.
154. Wang Y., Kreisberg J.I., Ghosh P.M. Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. Curr. Cancer Drug Targets 2007, 7:591-604.
155. Waterman M.L. Lymphoid enhancer factor/T cell factor expression in colorectal cancer. Cancer Metastasis Rev. 2004, 23:41-52.
156. Weaver R.E., Donnelly D., Wabitsch M., Grant P.J., Balmforth A.J. Functional expression of glucose-dependent insulinotropic polypeptide receptors is coupled to differentiation in a human adipocyte model. Int. J. Obes. (Lond.) 2008, 32:1705-1711.
157. Welters H.J., Kulkarni R.N. Wnt signaling: Relevance to beta-cell biology and diabetes. Trends Endocrinol. Metab. 2008, 19:349-355.
158. Wheeler M.B., Gelling R.W., Hinke S.A., Tu B., Pederson R.A., Lynn F., Ehses J., McIntosh C.H. Characterization of the carboxyl-terminal domain of the rat glucose-dependent insulinotropic polypeptide (GIP) receptor. A role for serines 426 and 427 in regulating the rate of internalization. J. Biol. Chem. 1999, 274:24593-24601.
159. Widenmaier S.B., Sampaio A.V., Underhill T.M., McIntosh C.H. Noncanonical activation of Akt/protein kinase B in {beta}-cells by the incretin hormone glucose-dependent insulinotropic polypeptide. J. Biol. Chem. 2009, 284:10764-10773.
160. Wolf D., Rodova M., Miska E.A., Calvet J.P., Kouzarides T. Acetylation of beta-catenin by CREB-binding protein (CBP). J. Biol. Chem. 2002, 277:25562-25567.
161. Wright W.S., Longo K.A., Dolinsky V.W., Gerin I., Kang S., Bennett C.N., Chiang S.H., Prestwich T.C., Gress C., Burant C.F., Susulic V.S., MacDougald O.A. Wnt10b inhibits obesity in ob/ob and agouti mice. Diabetes 2007, 56:295-303.
162. Xu G., Kaneto H., Laybutt D.R., Duvivier-Kali V.F., Trivedi N., Suzuma K., King G.L., Weir G.C., Bonner-Weir S. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: Possible contribution to impaired incretin effects in diabetes. Diabetes 2007, 56:1551-1558.
163. Yamada C., Yamada Y., Tsukiyama K., Yamada K., Yamane S., Harada N., Miyawaki K., Seino Y., Inagaki N. Genetic inactivation of GIP signaling reverses aging-associated insulin resistance through body composition changes. Biochem. Biophys. Res. Commun. 2007, 364:175-180.
164. Yamada Y. Incretin and bone. Clin. Calcium 2009, 19:1312-1317.
165. Yasuda K., Inagaki N., Yamada Y., Kubota A., Seino S., Seino Y. Hamster gastric inhibitory polypeptide receptor expressed in pancreatic islets and clonal insulin-secreting cells: Its structure and functional properties. Biochem. Biophys. Res. Commun. 1994, 205:1556-1562.
166. Yi F., Brubaker P.L., Jin T. TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta. J. Biol. Chem. 2005, 280:1457-1464.
167. Yip R.G., Boylan M.O., Kieffer T.J., Wolfe M.M. Functional GIP receptors are present on adipocytes. Endocrinology 1998, 139:4004-4007.
168. Yun M.S., Kim S.E., Jeon S.H., Lee J.S., Choi K.Y. Both ERK and Wnt/beta-catenin pathways are involved in Wnt3a-induced proliferation. J. Cell Sci. 2005, 118:313-322.
169. Zhou J., Livak M.F., Bernier M., Muller D.C., Carlson O.D., Elahi D., Maudsley S., Egan J.M. Ubiquitination is involved in glucose-mediated downregulation of GIP receptors in islets. Am. J. Physiol. Endocrinol. Metab. 2007, 293:E538-E547.